Why the study?
Does pegylated-liposomal doxorubicin exposure correlate with lesion response in patients with AIDS-related Kaposi's sarcoma?
Population
43 male patients with AIDS and at least five biopsy-proven cutaneous Kaposi's sarcoma lesions, median age 40…
Comparison
Pegylated-liposomal doxorubicin 10 or 20 mg/m2… vs null
Design
RCT, Randomized to receive either a 10 or 20 mg/m2 dose of study drug for…
Authors
Loading...
Supports Cmax,avg-guided dosing in AIDS-related Kaposi's sarcoma; confirms exposure-response relationship in RCT data.
Does pegylated-liposomal doxorubicin exposure correlate with lesion response in patients with AIDS-related Kaposi's sarcoma?
Pegylated-liposomal doxorubicin pharmacokinetics follow a two-compartment linear model, with lesion response predicted by Cmax,avg and dose intensity in AIDS-related Kaposi's sarcoma.
Amantea et al. (1997) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: